Lexi Ventures’ Post

ELISAs are a key tool in gene therapy research, delivering precise, quantitative measurements for targets with sensitive binding reagents. 🔬 Noble supports preclinical to phase 3 studies with tailored ELISA development and immunoassay services to meet your research needs. https://ow.ly/LoPt50UKi2q #cellandgene #immunoassay #genetherapy

At Franklin Biolabs, we partner with clients to accelerate novel cell and gene therapy (CGT) assets from clinical candidate to IND in 18 months. Our experienced team came from James M. Wilson, MD, PhD's academic program, a recognized leader in AAV-based genetic medicines and innovation supporting the global gene therapy industry with a proven track record of advancing discoveries to the clinic. We leverage our deep bench-to-bedside expertise in preclinical/translational studies, vector production & CMC, and bioanalytical research to provide comprehensive CGT solutions including worldwide clinical development. Learn more at https://lnkd.in/eTB7_C8Y Speak to a scientist about your project: info@franklinbio.com #CellAndGeneTherapy #AAV #ContractResearchOrganization

Did you know that Franklin Biolabs, a CRO spun out of University of Pennsylvania, was formerly known as Gene Therapy Program | University of Pennsylvania? Founded in 2024 by world-renowned gene therapy expert Dr. James M. Wilson, MD, PhD, who spent 30 years at Penn, this new venture aims to revolutionize gene therapy. Its sole investor is Savanne Life Sciences, the investment arm of the Mauritius-based Bioculture Group. Franklin Biolabs who operates out of The Discovery Labs in King of Prussia, PA provides specialized services in immunology, vector production and analytics, next-generation sequencing and bioinformatics, and nonclinical pharmacology and toxicology studies. The CRO partners with clients to accelerate novel cell and gene therapy (CGT) assets from clinical candidate to IND in 18 months. Leveraging its extensive bench-to-bedside expertise in preclinical/translational studies, vector production and CMC, and bioanalytical research, Franklin Biolabs provides comprehensive CGT solutions, including worldwide clinical development. The CRO conducts research for sponsors across several continents.

Owen Smith, Partner, sat down with Megan Thomas from Drug Discovery World to discuss 4BIO’s investment strategies and future trends in cell and gene therapy: https://lnkd.in/eaSTRWnh Key topics discussed include: ✅The promise of AAV gene therapies in non-renewing tissues and cell therapies in haematology ✅The challenges that the cell and gene therapy sector is experiencing and working to overcome ✅Regulatory and reimbursement complexities, especially in the EU #4BIO #Interview #Podcast #VC #AdvancedTherapies 

Do you know when companion diagnostics (CDx) are needed for your cell and gene therapy programs? Or what kind of testing is required and how to choose the right lab partner for a CDx assay? In our blog, you’ll learn from Labcorp subject matter experts as they answer key questions you may have about developing CDx for your cell and gene therapy programs. #CellandGeneTherapy #CompanionDiagnostics

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Significant advances in upstream biomanufacturing methods for cell and gene therapies have been achieved in recent years. However, final yields continue to be impacted by losses in downstream steps. Interferometric light microscopy (ILM) represents a fast and cost-effective method for process development teams to obtain size and concentration data within seconds. Learn more in this upcoming webinar with Cell & Gene Therapy Insights presented by Benjamin Josey: http://ms.spr.ly/6045WHOvb

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy